+ subset. Altogether, our data demonstrate for the first time in a randomized setting that homeostasis of the T cell pool is less altered early after BCT than after BMT. This may have a strong impact on the graftversus-leukemia (GVL) effect and subsequent relapse rate. Bone Marrow Transplantation (2001) 27, 167-175.
Allogeneic peripheral blood stem cells (PBSC) mobilized by administration of recombinant human granulocyte colony-stimulating factor (G-CSF) in HLA-identical healthy sibling donors is being considered as an alternative approach to bone marrow transplantation (BMT), supporting a rapid and durable engraftment, with both neutrophil and platelet reconstitution. [1] [2] [3] PBSC harvests contain about 10-fold more T cells 4, 5 than bone marrow (BM) harvests. Despite this large T cell content, initial clinical results indicate that the incidence of acute graft-versus-host disease (aGVHD) is not higher when compared with allogeneic BMT. 1, [5] [6] [7] [8] It may also be expected that the larger lymphocyte dose in PBSC apheresis products could lead to a more pronounced graft-versus-leukemia (GVL) effect or may allow for a better protective immunity against infection. 3, 9 Indeed, peripheral blood lymphocyte counts 1 month post BMT have been reported to be of crucial importance for the prediction of a GVL effect. 10 In the few non-randomized studies performed to date, T cell counts are higher after allogeneic BCT than after allogeneic BMT, 11, 12 which is in accordance with preliminary data reporting a more potent GVL effect of BCT than BMT. 13 However, detailed analysis of the T cell pool after BCT vs BMT in a randomized study is still lacking.
The Société Française de Greffe de Moelle (SFGM) has completed a multicentric randomized phase III clinical trial aimed at comparing allogeneic BMT to allogeneic BCT after G-CSF mobilization in an HLA-identical setting. 14 We have taken advantage of this study to analyze immune cell recovery 30 days after transplantation, since peripheral blood lymphocyte counts at this time are predictive of a GVL effect. 10 The phenotypes of immune cells present in the peripheral blood before and 30 days after transplantation were determined and compared in 46 evaluable consecutive patients (BMT: n = 26; BCT: n = 20) entered in the clinical trial. In addition, immunophenotyping was performed on the hematopoietic stem cell (HSC) grafts, as well as the peripheral blood of the 46 donors. We report here that, in addition to resulting in larger counts of circulating T cells, BCT allows for weaker alterations of early T cell compartment homeostasis than BMT.
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Patients, materials and methods
Design of the study
A multicentric phase III randomized clinical trial was conducted by the SFGM in order to compare allogeneic BMT to G-CSF-mobilized BCT in an HLA-identical setting (SFGM-CSF 315, coordinators: Drs M Kuentz and D Blaise). 14 The protocol was approved by the local ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Marseille 2). One hundred and thirty-six patients from 17 centers affiliated to the SFGM were centrally randomized as previously described.
14 Seventy-two consecutive patients (BMT: n = 37; BCT: n = 35) were included in a biological study aimed at characterizing the immune cells in the graft and in the blood after HSC transplantation (median: three patients/transplant center). Forty-six patients (BMT: n = 26; BCT: n = 20) were available for evaluation of post-transplant immune cell recovery. The other remaining patients were either subsequently excluded from the clinical trial for non-compliance, infection, hematological relapse at time of transplantation (BMT: n = 5; BCT: n = 8) or were not analyzable because of nonavailable samples (BMT: n = 6; BCT: n = 7). Donor and recipient-derived samples (see below) were centralized and analyzed at the Etablissement Français du Sang-Bourgogne/Franche-Comté (Besançon, France).
Patient eligibility
To be eligible, patients had to be aged under 55 years and suffer from acute leukemia (AL) (myeloid (AML); lymphoblastic (ALL)) in first (CR1) complete remission or second (CR2) complete remission or from chronic myeloid leukemia (CML) in first chronic phase (CP1). They had to have an HLA A, B, DR matched sibling donor, aged at least 18 years. HLA typing was determined serologically for A and B loci, and molecularly for the DR locus. In addition, patients had to satisfy the common clinical and biological criteria usually required to receive an allogeneic transplant. All donors and recipients gave their written informed consent. Characteristics of the donors and recipients are described in Table 1 .
Conditioning regimen
Depending on disease status and center programs, different myelo-ablative treatments were used. 14 The majority (BMT: n = 19; BCT: n = 15) were prepared with a total body irradiation (TBI)-based conditioning regimen, associating TBI with either cytoxan Ϯ etoposide, or melphalan + cytarabinoside (Table 1) . The remaining patients (BMT: n = 7; BCT: n = 5) were not treated with TBI, but instead received chemotherapy associating busulfan and cytoxan.
Graft collection and reinfusion
The day of cell infusion was designated as day 0. In the BCT group, mobilization consisted of daily subcutaneous administration of lenograstim, a glycosylated G-CSF (kindly provided by Laboratoire Rhône-Poulenc-Rhorer, Montrouge, France) at a dose of 10 g/kg. Treatment started on day −5 and ended on day −1. As per protocol, the collection of at least 4 × 10 6 CD34/kg in two cytaphereses was sought with a maximum of three cytaphereses. The first cytapheresis was performed on day −1, kept overnight at 4°C and reinfused on day 0 with the second one. For one donor, a third cytapheresis was performed and infused on day 1 after one more injection of lenograstim to the donor on day 0. In the BMT group, a harvest of at least 2 × 10 8 nucleated cells per kg was requested and autologous blood transfusion was usually performed. In both groups, cells were harvested and processed according to the standard procedures of the center and the whole harvest was reinfused.
GVHD prophylaxis
All recipients received post-graft immunosuppression consisting of 'short' course methotrexate (days 1, 3 and 6) and cyclosporin A. Cyclosporin A was started intravenously on day −1 at a dosage of 2 to 3 mg/kg and switched to oral formulation as soon as oral intake was appropriate. Dosage was adapted to blood levels and renal function, according to center practice. Acute GVHD was evaluated according to the standard gradation. 15 
Supportive care
Patient management was performed according to the standard procedure of each center and was expected to be the same in the two groups for a given center. In particular, post-transplant G-CSF was not systematically allowed and was restricted to the decision of the attending physician in specific situations (eg notably for patients who did not reach 0.5 × 10 9 neutrophils/l on day 21). Two patients in each group received G-CSF on day 30 or at any given time before day 30 sampling. For all parameters analyzed, these patients were not significantly different from others and were not excluded from analysis. No patient received donor T cell add-back by day 30.
Biological samples
Citrate-anti-coagulated (Vacutainer; Becton Dickinson, Le Pont de Claix, France) peripheral blood (PB) was obtained from the BM donors before or at the time of BM harvest, from PBSC donors before and after G-CSF mobilization (ie before the first apheresis), and from recipients before conditioning and on day 30 post transplantation. One to 5 ml HSC samples were also obtained from the BM graft and from each cytapheresis product. Detailed analysis of the HSC grafts has been described elsewhere. 16 The use of citrate as the blood anticoagulant was chosen in order to be homogeneous with the BM and PBSC grafts, which were collected in a bag containing citrate.
Analysis of cell surface markers
HSC samples were diluted 10-fold in 0.9% NaCl before staining. Fifty l of whole blood or diluted HSC samples were incubated with 10 l of monoclonal antibodies (mAbs) with the following combinations: CD3-FITC associated with control IgG1-PE, CD25-PE, CD45RA-PE, CD45RO-PE, CD95-PE, TCR␥␦-PE or HLA-DR-PE, CD4-FITC/CD8-PE/CD3-PerCP, CD8-FITC/CD56-PE/CD3-PerCP and CD45-RA-FITC/CD45RO-PE/CD4-PE-Cy5. Red blood cells were lysed with FACS Lyzing solution (Becton Dickinson). After washing in PBS buffer supplemented with 1% w/v BSA and 0.1% sodium azide (PBS/BSA/NaN 3 ), cells were fixed in PBS/BSA/NaN 3 containing 1% v/v formaldehyde and analyzed by flow cytometry with a FACScalibur (Becton Dickinson). A minimum of 5000 lymphocyte-gated events was acquired. Monocytes were determined according to size and granularity parameters and high expression of CD14. Acquisition and analysis were performed with CellQuest software (Becton Dickinson). Data were expressed as the percentage of positive cells or as the ratio of the mean fluorescence intensity (MFI, linear values) of labelled cells to the MFI of control Ig-labelled cells. The CD3-FITC/CD95-PE labelling was not performed at the initiation of the study but was included in the panel later. Therefore, data for CD95 expression are representative of 13 consecutive recipients per arm of randomization. Additional CD45RA-FITC/CD45RO-PE/CD4-PECy5 triple labelling was performed on randomly selected frozen PBMC from six consecutive recipients per arm of randomization. All antibodies were purchased from Diaclone (Besançon, France), except CD3-PerCP and TCR-␥␦-PE (Becton Dickinson) and CD4-PECy5 (Immunotech, Marseille, France).
Bone Marrow Transplantation
Cell counts
Cell counts were performed with a SF3000 cell counter (Sysmex, Kobe, Japan) on all samples. HSC samples were previously diluted 10-fold in 0.9% NaCl. The circulating cell counts and absolute quantities of infused cells per kg of recipient were calculated for each cell subset from cytometry analysis and cell counts.
Statistical analysis
Statistical analyses were performed with the SigmaStat software (Jandel Scientific, Erkrath, Germany). Biological data of the BM group were compared to those of the PBSC group using the Mann-Whitney rank sum test, whereas comparison of data within each group was done using a paired t-test. Repartitions of donors or recipients were compared between both arms of randomization using the chisquare test; correlation analyses were performed with a Pearson correlation test.
Results
Hematopoietic stem cell grafts
Absolute numbers of infused cells per kg of recipient were significantly higher in the PBSC harvests than in the BM harvests ( Table 2 ). The CD34 + cell counts were 3.1-fold higher in the PBSC products than in the BM harvests. Infused monocyte and lymphocyte counts were, respectively, 29.8-and 7.3-fold higher in the PBSC grafts than in the BM grafts. Lastly, the number of T cells (CD4 + , CD8 + , CD45RA + or CD45RO + ), B cells and NK cells were approximately one log more abundant in the PBSC graft when compared to the BM graft.
Blood cell counts 30 days after transplantation
We analyzed the blood cell counts of monocytes, NK cells, B cells and T cells expressing either subset markers (CD3 associated with TCR ␥␦, CD4, CD8, CD45RA, CD45RO or CD56) or activation markers (CD25, HLA-DR and CD95). For all cell subsets studied, blood cell counts and relative subset repartition did not differ between PBSC and BM donors or between PBSC and BM recipients, thus demonstrating that donors' and recipients' randomization were correct (data not shown). Two/26 BM-and 2/20 PBSCtransplanted patients received G-CSF before or at the time of day 30 sampling, but were not excluded from analysis.
Absolute cell counts were higher 30 days after allogeneic BCT than after BMT for total lymphocytes (BCT: 1127 Ϯ 158; BMT: 623 Ϯ 80 cells/l; P = 0.013), B lymphocytes (BCT: 14 Ϯ 5; BMT: 4 Ϯ 3 cells/l; P = 0.008) and T lymphocytes (BCT: 718 Ϯ 142; BMT: 271 Ϯ 53 cells/l; P = 0.006), while monocyte and NK cell counts were not statistically different on day 30 between PBSC-and BMtransplanted patients (Table 3) .
Cell counts were significantly higher in the BCT group than in the BMT group for most of the analyzed T cell subpopulations: CD3 + HLA-DR + cell counts were similar for both groups.
Powles et al 10 reported that the probability of AML relapse 29 days after allogeneic BMT was lower for patients with lymphocyte counts above 200 cells/l. In our study, the repartition of patients with lymphocyte counts Ͼ200 cells/l was similar for the two groups (BMT: 22/26, BCT: 19/20, P = NS). However, when CD3
+ cell counts were used instead of lymphocyte counts, 8/26 BM-transplanted patients (30.8%) had a CD3
+ cell count Ͼ200/l vs 15/20 patients (75.0%) in the BCT group (P = 0.007).
Expression of T cell activation markers
We compared the expression of three activation markers (HLA-DR, CD95 and CD25) 30 days after transplantation in the two groups of recipients ( Figure 1 ). Peripheral blood T cells obtained from BM donors or PBSC donors before G-CSF mobilization were used as a reference. Both frequency of positive cells and the level of expression of activation markers, evaluated by the MFI of positive T cells, were analyzed.
Post-BMT T cells were more activated than post-BCT T cells, since the frequency of HLA-DR + and of CD95 + cells was higher within post-BMT T cells than within post-BCT T cells. The frequency of CD25
+ T cells was similar between both groups, but these cells expressed the CD25 at a higher density after BMT than after BCT, as revealed by the higher CD25 MFI on CD25 + T cells of BMtransplanted recipients.
Further confirmation that the T cell activation level was higher after BMT than after BCT arose from the comparison of recipients' cells to donors' cells, using a paired ttest. Indeed, only the frequency of CD95 + T cells, and not HLA-DR + or CD25 + T cells, was enhanced after BCT, whereas the frequency of all three subsets increased after BMT. Lastly, the expression level of these three markers did not increase after BCT, as compared with normal MFI values, whereas CD25 and CD95 expression levels were significantly higher in post-BMT cells than in donors' cells.
Altogether, these data strongly support the notion that peripheral T cells are activated early after transplantation, but that the level of activation is much higher after BMT than after BCT.
Expression of naive vs memory markers
Naive vs memory/recently activated T cells were analyzed using double staining with CD3 and CD45 mAbs ( Figure  2 ). The frequency of CD3 + CD45RO + cells was higher in BM-transplanted recipients than in PBSC-transplanted recipients (Figure 2b) , whereas the frequency of CD3 T cells (Figure 2b) . Thus, CD3
+ CD45RO + cells behaved in a different way in the two randomization arms.
Correlation between the infused cell numbers and posttransplant counts
We hypothesized that the higher CD3 + CD4 + and CD3 + CD8 + cell counts observed after BCT vs BMT (Table 3 ) could result from the fact that 13.3-and 8.7-fold more CD3 + CD4 + and CD3 + CD8 + cells, respectively, were infused with the PBSC grafts compared to the BM grafts ( Table 2 ). In order to determine whether there is a correlation between the number of injected T cells and T cell recovery at day 30, we plotted the number of infused cells vs the cell count at day 30 post transplant. A positive and significant correlation was observed in the BCT group for the CD3 + CD4 + (Figure 3a) , the CD3 + CD8 + (Figure 3b ) and the CD3 + CD45RA + (Figure 3c ) subsets, but not for the CD3 + CD45RO + subset (Figure 3d) , demonstrating that the more of these cells were infused, the more they were recovered at day 30 post transplant. Thus, the number of infused T cells seems to be predictive of the post-BCT T cell counts. By contrast, no correlation could be observed in the BMT arm, whatever the T cell subset, suggesting that post-transplant T cell lymphopoiesis or peripheral expansions and/or deletions occurred randomly after BMT, thereby affecting the post-transplant cell recovery in a different way than after BCT. There was no correlation, in either arm, between the number of infused CD34
+ cells and the post-transplant T cell counts (data not shown), suggesting that early T cell counts did not derive from lymphopoiesis. Despite the fact that around 10-fold more T cells were infused with a PBSC graft than with a BM harvest (Table  2) , cell counts were only two-fold higher after BCT than after BMT (Table 3 ). This observation suggests that the impact of peripheral expansion and/or deletion was not the same in the two arms. Thus, we calculated, for each patient, the ratio between the post-transplant cell count (expressed as the number of circulating cells/l) and the number of infused cells (expressed as 10 6 cells/kg) for CD4 + , CD8 + , CD45RA
+ and CD45RO + T cells. As reported in Table 4 , the ratio for CD3 + cells was 2.0 Ϯ 0.4 in the PBSC arm Table 4 Ratio between day 30 blood counts and the number of infused cells at day 0
a Data are expressed as the ratio (mean ± s.e.) between the day 30 blood counts (expressed as cell number/l) and the number of cells (×10 6 /kg) infused with the graft. and was significantly higher (13.3 Ϯ 3.2; P Ͻ 0.001) in the BM arm. Similar results were obtained for the analyzed T cell subsets (Table 4 ). This demonstrates, by normalizing the post-transplantation T cell counts to the same amount of infused T cells, that T cell expansion is greater after BMT than after BCT.
However, such analysis may be biased by the simultaneous assay of the CD4 and CD8 or of the CD45RA and CD45RO T cell subsets. Thus, a three-color staining (CD45RA/CD45RO/CD4) was performed on 12 consecutive randomly selected post transplant (BMT: n = 6; BCT: n = 6) frozen PBMC samples and their corresponding HSC samples, in order to confirm our hypothesis. Since CD45RO expression has been shown to be reversible on CD8 + T cells, 19 but not on CD4 + cells, 20 we focused our analysis on this subset (Figure 4) . The ratio of blood cell counts on day 30 to the infused cell numbers was calculated for each CD4 + subset (CD45RA + /RO Ϫ , CD45RA + /RO + and CD45RA Ϫ /RO + within the CD4 + cells). In the BM arm, this ratio was high in the CD45RA Ϫ /RO + subset (82.5 Ϯ 31.5), intermediate in the CD45RA + /RO + subset (18.4 Ϯ 5.4), and low in the CD45RA + /RO Ϫ subset (4.2 Ϯ 1.5, Figure 4 ). In the BCT arm, the highest ratio was also observed in the CD45RA Ϫ /RO + subset (8.4 Ϯ 3.5), but was similar in the CD45RA + /RO + (1.8 Ϯ 0.8) and the CD45RA + /RO Ϫ subsets (1.6 Ϯ 0.4). The observation that, for each subset (especially in the CD45RA + /RO + and CD45RA Ϫ /RO + subsets), the ratio was much higher in the BM arm than in the PBSC arm further strengthened the view that peripheral expansion of the T cell pool was more pronounced after BMT than after BCT.
Discussion
Although hematological reconstitution after allogeneic BCT has been extensively analyzed, 11, 12 our study is the first direct comparison of immune cell recovery after BMT vs BCT in a randomized setting. Whereas monocytes and NK cell counts are similar between both groups 1 month after transplant, peripheral T cell counts are significantly higher after BCT than after BMT. These differences remain significant for CD4 + , CD8 + , CD45RA + and CD45RO + subsets and could be explained by several, non-exclusive, hypotheses. First, the infusion of more hematopoietic precursors with PBSC may improve and accelerate lymphopoiesis in the BCT arm. This seems unlikely, since there was no correlation between the number of infused CD34
+ cells and the post-transplant T cell counts. Second, the higher T cell counts may result from the higher number of infused T cells in the BCT arm. Third, peripheral expansion of infused T cells may occur at a different intensity after BCT and after BMT. It has been shown in murine models that post-BMT peripheral T cell expansion takes place regardless of the size of the initial T cell inoculum, 21, 22 and that the T cell population will grow until it has reached a threshold level. However, transfer experiments with a large T cell inoculum did not produce such an expansion. 20 Similarly, one could speculate that T cells may have a lower proliferation rate after BCT than after BMT as a result of being infused in greater numbers, so that the T cell compartment would be closer to the final 'threshold size' it has to reach. Thus, the requirement for post-transplant peripheral expansion would be less pronounced after BCT, since T cells would have less 'vital space' to recolonise. Our data are in agreement with this hypothesis and demonstrate, at least in the CD4 + cell compartment, that post-transplant expansion and/or deletions may exist whatever the HSC source, but may be of greater significance early after BMT than after BCT. Several observations support this hypothesis.
First, T cells were more activated after BMT than after BCT, as evaluated by a higher percentage of CD45RO + , HLA-DR + and CD95 + T cells and a higher MFI of CD25 staining in the former group. This observation is in agreement with the hypothesis of a more pronounced peripheral proliferation.
Second, CD3 + CD4 + , CD3 + CD8 + and CD3 + CD45RA + counts after BCT directly correlated with the infused cell numbers from the PBSC harvest. The observation that, for these T cell subsets, the number of infused cells is predictive of the post-BCT cell counts suggests that these cells are subject to limited post-transplant clonal expansion or deletions. By contrast, there was no correlation between the number of infused CD4 + , CD8 + , CD45RA + or CD45RO + T cells and the blood counts at day 30 post-BMT, suggesting that the T cell compartment was more affected by expansions or deletions after BMT than after BCT. It remains possible, however, that a weaker correlation may exist after BMT, but that such a correlation was missed due to insufficient number of samples in our study.
Third, when the post-transplant T cell recovery (ie blood cell counts 30 days after transplantation) was normalized to the initial T cell input (ie numbers of T cells infused with the graft), the ratio was higher in the BM arm than in the PBSC arm, demonstrating that, for an equal number of infused T cells, cell recovery was much higher 30 days after BMT than after BCT. 25, 26 Another important finding of this study, in accordance with recent reports, [27] [28] [29] was that the frequency of CD95 + cells was highly increased after BMT. Spontaneous T cell apoptosis [27] [28] [29] and AICD 27, 28 have also been reported as increased after BMT, but only AICD correlated with the CD95 expression level 27 and was CD95-dependent, 29 whereas spontaneous apoptosis was associated with a decreased bcl-2 expression. 27, 28 We show moreover that the increase of the CD95 + T cell percentage was moderate after BCT and was less pronounced than after BMT. This suggests that post-BCT T cells may be less susceptible to AICD than post-BMT T cells. However, sensitivity of post-BCT T cells to spontaneous apoptosis or AICD, as well as their bcl-2 expression level, remain to be determined.
It should be emphasized that our observations concern only the early phase of immune reconstitution and that the differences observed between BMT and BCT may not exist later. A study involving a kinetic analysis, with early, intermediate and late time points, could be of value to confirm our results. However, a number of recent findings suggest that an increased number of circulating T cells present early after allogeneic HSC transplantation, as shown in our study, could have significant clinical consequences later. Indeed, low CD4
+ counts (Ͻ200 cells/l) after unrelated BMT have been strongly associated with the risk of life-threatening opportunistic infection. 30 In addition, it has been recently shown that the probability of relapse was significantly higher for the patients with a low lymphocyte counts early after BMT. 10 In this study, the 3-year relapse probability was 42% for patients with an absolute lymphocyte count Ͻ200/l at day 29 vs 16% for patients with у200 lymphocytes/l. Interestingly, a recent study by Elmaagacli et al 31 suggests that BCT may be associated with a lower relapse risk in CML patients. Lastly, a recent summary of registry data suggests a survival advantage during the early post-transplant period after BCT, particularly in high-risk patients. 32 Overall, our data demonstrate for the first time in a prospective randomized study that the use of an allogeneic PBSC graft results in enhanced immune cell recovery 1 month after transplant when compared to the use of a marrow graft. Infusion of higher T cell numbers with a G-CSF mobilized PBSC graft than with a BM graft may limit their post-transplant expansion and peripheral deletions, leading to more numerous, naive and less activated T cells than after BMT. Such an enhanced immune cell recovery could have significant clinical relevance.
